Ongoing Phase Ib/IIa study in Subarachnoid Hemorrhage (SAH). Phase Ib part completed with no adverse drug reactions detected. Edvince has strong commercial protection for both SAH indication and orphan drug designation in EU and US – market exclusivity and potential for compassionate use during clinical development.
New projects in our pipeline designed for i.v. administration
Opportunity to expand into other stroke indications, including global ischemic stroke, with high market potential (200,000 yearly incidents in the US alone).
* Emergency medication e.g. in ambulance
** Based on well-known small molecules.